Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 15/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitifadine SCHEMBL79279 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL30231901 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378242 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855350 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855353 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL8213058 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL12313135 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL9604846 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL29393526 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL4552778 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | claimed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4590287-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | Brightseed, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | BRIGHTSEED, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMA (US) LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240307336-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | EPITRACKER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4410380-A2 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | Anji Pharmaceuticals Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410285-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC SYNDROME | Government Of The United States Of America As Represented By The Secretary Of the Navy (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007127396-A1 | PROCESS FOR THE SYNTHESIS OF (+) AND (-) -1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE | DOV PHARMACEUTICAL, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006136223-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006133946-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006108700-A1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A2 3023/4885SLC6A4 2230/4885SLC6A3 982/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | SLC6A2 2433/4885SLC6A4 3210/4885SLC6A3 1448/4885 |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | SLC6A2 478/4885SLC6A4 415/4885SLC6A3 15/4885 |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | SLC5A2, SLC10A1, GPR119 | SLC6A2 415/4885SLC6A4 381/4885SLC6A3 788/4885 |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | FABP2, VIP, SI | SLC6A2 968/4885SLC6A4 1221/4885SLC6A3 2081/4885 |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | SLC6A2 988/4885SLC6A4 652/4885SLC6A3 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.